Delving into the Latest Updates on Pinotbio, Inc. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Respiratory Diseases

Antibody drug conjugate (ADC)

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	10
Hemic and Lymphatic Diseases	2

Top 5 Drug Type	Count

Antibody drug conjugate (ADC)	8
Small molecule drug	4

Top 5 Target	Count

DNMT1(DNA (cytosine-5)-methyltransferase 1)	2
11β-HSD1(Corticosteroid 11-beta-dehydrogenase isozyme 1)	2
nectin-4	1
c-Met(Hepatocyte growth factor receptor)	1
HER2(Receptor tyrosine-protein kinase erbB-2)	1

A Phase 1/2, Open-label, Dose-exploration and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTX-301 Monotherapy in Advanced Solid Tumours, and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer, and in Combination With Temozolomide as Adjuvant (Maintenance) Therapy in High-grade Glioma (Optional Arm)

This is a Phase 1/2, open-label, dose-exploration, combination/expansion study, which will start by evaluating the safety and tolerability of NTX-301, an oral DNMT1 inhibitor, as a monotherapy in patients with advanced solid tumours, who have failed treatment with available therapies known to be active for treatment of their corresponding disease. It will then explore the safety and tolerability of NTX-301 in combination with platinum-based therapy in patients with ovarian and bladder cancer. Optionally, the safety and tolerability of NTX-301 in combination with Temozolomide (TMZ) in patients with Isocitrate Dehydrogenase 1 (IDH1) mutated high-grade glioma will also be assessed.

Start Date25 Aug 2021

Sponsor / Collaborator

Xennials Therapeutics, Inc.

[+1]

NCT05041543

/ CompletedPhase 1

A Randomized, Double-blinded, Placebo-controlled, Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety and Tolerability of NTX-101 in Healthy Volunteers

A double-blinded, placebo controlled, multiple dose, randomized, single site, phase 1 clinical trial to evaluate safety, tolerability, and pharmacokinetics of NTX-101 topical eye drop in Korean healthy volunteers

Start Date02 Mar 2021

Sponsor / Collaborator

Pinotbio, Inc.

100 Clinical Results associated with Pinotbio, Inc.

Login to view more data

0 Patents (Medical) associated with Pinotbio, Inc.

Login to view more data

100 Deals associated with Pinotbio, Inc.

Login to view more data

100 Translational Medicine associated with Pinotbio, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

9

1

Phase 1

Phase 2

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

NTX-101 ( 11β-HSD1 )	Glaucoma More	Phase 2
AST-081 ( DNMT1 )	Acute Myeloid Leukemia More	Phase 1
PBX-003	Head and Neck Neoplasms More	Preclinical
PBX-CT01 ( c-Met )	Bladder Cancer More	Preclinical
PBX-CT-02 ( nectin-4 )	Non-Small Cell Lung Cancer More	Preclinical